Clinical Rheumatology · Nov 19, 2026
Associations of cigarette smoking, e-cigarette use, and dual use with newly diagnosed arthritis: a longitudinal cohort analysis
By Adebisi YA, Alhur AA, Ogunkola IO et al.
Introduction: Cigarette smoking is an established risk factor for rheumatoid arthritis, but longitudinal evidence on e-cigarette use, dual use, and broader arthritis outcomes remains limited. We examined whether baseline cigarette and e-cigarette use status was associated with newly diagnosed arthritis reported at follow-up. Methods: We analysed data from the UK Household Longitudinal Study (UKHLS) among participants who did not report a previous arthritis diagnosis at Wave 10 (2018–2019; baseline). Baseline cigarette and e-cigarette use was classified into four mutually exclusive groups: neither current cigarette nor e-cigarette use, exclusive current cigarette use, exclusive current e-cigarette use, and dual use. The outcome was newly diagnosed arthritis reported at Wave 14 (2022–2023; follow-up). Modified Poisson regression with robust standard errors was used to estimate risk ratios (RRs) and 95% confidence intervals. Adjusted models included age modelled using a four-knot restricted cubic spline, sex, ethnicity, rural–urban residence, and highest educational qualification. Sensitivity analyses additionally adjusted for alcohol use and fruit and vegetable intake measured at Wave 9, excluded participants who reported arthritis at Waves 11–13, and applied stricter e-cigarette-use definitions. Results: Among 18,802 participants included in the primary analysis, 587 (3.12%) reported newly diagnosed arthritis at Wave 14. The unadjusted proportions were 3.05% among participants reporting neither current cigarette nor e-cigarette use, 3.83% among exclusive cigarette users, 2.21% among exclusive e-cigarette users, and 4.47% among dual users (overall p = 0.064). Compared with participants reporting neither current cigarette nor e-cigarette use, exclusive cigarette use was associated with a higher adjusted risk of newly diagnosed arthritis (RR 1.43, 95% CI 1.11–1.84; p = 0.005), as was dual use (RR 1.79, 95% CI 1.10–2.90; p = 0.019). Exclusive e-cigarette use was not associated with newly diagnosed arthritis (RR 1.01, 95% CI 0.61–1.68; p = 0.965). Compared with the primary analysis, estimates were similar after additional adjustment for alcohol use and fruit and vegetable intake (exclusive cigarette use: RR 1.39, 95% CI 1.06–1.82; p = 0.017; dual use RR 1.79, 95% CI 1.09–2.94; p = 0.022) and after excluding participants who reported arthritis at Waves 11–13 (exclusive cigarette use: RR 1.50, 95% CI 1.09–2.06; p = 0.012; dual use: RR 1.92, 95% CI 1.03–3.57; p = 0.040). When e-cigarette use was restricted to at least monthly or weekly use, the association for exclusive cigarette use remained stable, exclusive e-cigarette use showed no evidence of an association, and the dual-use estimates were attenuated and less precise. Conclusions: Exclusive cigarette smoking and dual cigarette-e-cigarette use were associated with a higher risk of newly diagnosed arthritis in the primary analysis. No association was identified for exclusive e-cigarette use, although precision was limited. Studies with clinically verified arthritis outcomes, repeated exposure assessment, and stronger control of cumulative smoking and adiposity are needed. <table-wrap> Key Points • Exclusive cigarette use was associated with a 43% higher adjusted risk of newly diagnosed arthritis. • Dual cigarette and e-cigarette use was associated with a 79% higher adjusted risk in the primary analysis. • Exclusive e-cigarette use was not associated with newly diagnosed arthritis, but the estimate was imprecise. • Dual-use estimates weakened when e-cigarette use was restricted to at least monthly or weekly use. </table-wrap>
doi.org/10.1007/s10067-026-08544-7Open accessPubMed 43055897Populations